Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 11:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 5,259 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Autoimmune Disease Clear all
Completed Phase 2 Interventional Results available

Study Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550

NCT01059864
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550, Atorvastatin, Atorvastatin Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
10
States / cities
Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2012 · Synced Oct 21, 2026, 11:15 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Yoga: Effect on Attention in Aging & Multiple Sclerosis

NCT00010998
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Yoga
Procedure
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
65 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2004
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 21, 2026, 11:15 PM EDT
Completed Phase 1 Interventional

Assessing the Suitability of an Imaging Probe for Use in Clinical Cell and Gene Therapy Trials in Cancer and Rheumatoid Arthritis

NCT00185848
View directory record Official record
Conditions
Brain Cancer, Arthritis, Rheumatoid, Central Nervous System Neoplasms, Glioma
Interventions
[18F]FHBG
Radiation
Lead sponsor
Sanjiv Sam Gambhir
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
2
States / cities
Los Angeles, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 21, 2026, 11:15 PM EDT
Terminated Phase 2 Interventional Results available

Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders

NCT05086744
View directory record Official record
Conditions
Immune Thrombocytopenia (ITP), Cold Agglutinin Disease (CAD)
Interventions
Iptacopan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 120 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 21, 2026, 11:15 PM EDT
Completed Phase 2 Interventional Results available

Eltrombopag for Moderate Aplastic Anemia

NCT01328587
View directory record Official record
Conditions
Moderate Aplastic Anemia, Unilineage Bone Marrow Failure Disorders
Interventions
Eltrombopag
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 100 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 21, 2026, 11:15 PM EDT
Completed Not applicable Interventional

Effects of a Home Based Walking Program Using Rhythmic Auditory Stimulation in Patients With Multiple Sclerosis

NCT02065284
View directory record Official record
Conditions
Multiple Sclerosis, Ambulation Difficulty
Interventions
Rhythmic Auditory Stimulation (RAS)
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 21, 2026, 11:15 PM EDT
Completed Phase 1 Interventional

A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis

NCT01417052
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
50 mg LX3305 QD, 100 mg LX3305 QD, 150 mg LX3305 QD, 200 mg LX3305 QD, 250 mg LX3305 QD, 300 mg LX3305 QD, 400 mg LX3305 QD, 250 mg LX3305 BID, 500 mg LX3305 QD, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Oct 21, 2026, 11:15 PM EDT
Completed Not applicable Interventional Results available

Feasibility and Acceptability of PREVAIL (PREserving Valued Activities In Life)

NCT06706999
View directory record Official record
Conditions
Rheumatoid Arthritis (RA), Arthritis, Rheumatoid (RA)
Interventions
PREVAIL model of care
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 21, 2026, 11:15 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease

NCT07061938
View directory record Official record
Conditions
IgG4 Related Disease
Interventions
ACE1831, Lymphodepleting chemotherapy
Drug
Lead sponsor
Acepodia Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Atlanta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 21, 2026, 11:15 PM EDT
Completed Phase 2 Interventional Results available

Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks

NCT00147498
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
24
States / cities
Upland, California • Clearwater, Florida • Miami, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Oct 21, 2026, 11:15 PM EDT
Terminated Phase 2 Interventional Results available

An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis

NCT03943147
View directory record Official record
Conditions
Lupus Nephritis
Interventions
BMS-986165, Placebo, Mycophenolate Mofetil
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
40
States / cities
Birmingham, Alabama • Fresno, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Oct 21, 2026, 11:15 PM EDT
Completed Phase 4 Interventional

Efficacy and Safety of Valdecoxib and Naproxen in Treating the Signs and Symptoms of Rheumatoid Arthritis (RA) in a Severe Rheumatoid Arthritis Patients

NCT00650455
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
valdecoxib, naproxen, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
489 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
52
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2008 · Synced Oct 21, 2026, 11:15 PM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

GLP-1 RA for Stage 1 Type 1 Diabetes

NCT07430332
View directory record Official record
Conditions
Stage 1 Diabetes Mellitus, Type 1
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2030
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 21, 2026, 11:15 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Immune Profiles in Multiple Sclerosis (MS) Patients and Healthy Volunteers Through Thoracic Duct Cannulation

NCT05162638
View directory record Official record
Conditions
Multiple Sclerosis, Healthy
Interventions
thoracic duct cannulation
Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 21, 2026, 11:15 PM EDT
Completed Not applicable Interventional

Home Telemedicine to Optimize Health Outcomes in High-Risk Youth With Type 1 Diabetes

NCT03324438
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Home Telehealth T1D C2oYoT1-HR, Personalized Behavioral Health, Personalized Adherence Feedback
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
10 Years to 17 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 21, 2026, 11:15 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

The Role of Amylin and Glucagon in T1DM

NCT00206258
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Pramlintide and glucagon
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 21 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 21, 2026, 11:15 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus (DM)

NCT01672255
View directory record Official record
Conditions
Type 1 Diabetes, Hypoglycemia Associated Autonomic Failure
Interventions
Fluoxetine, Placebo control
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 21, 2026, 11:15 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications

NCT00856544
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CP-690,550, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
795 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
46
States / cities
Huntsville, Alabama • Jonesboro, Arkansas • Palo Alto, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 21, 2026, 11:15 PM EDT
Completed Phase 3 Interventional Results available

Randomized Study of Real-Time Continuous Glucose Monitors (RT-CGM) in the Management of Type 1 Diabetes

NCT00406133
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Continuous glucose monitor
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
8 Years and older
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
11
States / cities
Beverly Hills, California • San Diego, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2017 · Synced Oct 21, 2026, 11:15 PM EDT
Completed Phase 1Phase 2 Interventional

Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

NCT01713738
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura (ITP), Immune Thrombocytopenic Purpura (ITP)
Interventions
rituximab
Drug
Lead sponsor
Neufeld, Ellis J, MD, PhD
Individual
Eligibility
18 Months to 18 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2012 · Synced Oct 21, 2026, 11:15 PM EDT
Completed Phase 3 Interventional Results available

Aspirin for Exercise in Multiple Sclerosis (ASPIRE)

NCT03824938
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Aspirin 650mg Oral Capsule, Acetaminophen Tablet 650mg, Placebo
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 21, 2026, 11:15 PM EDT
Recruiting No phase listed Observational

A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.

NCT06299748
View directory record Official record
Conditions
Myasthenia Gravis, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
Efgartigimod
Biological
Lead sponsor
argenx
Industry
Eligibility
Female only
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 21, 2026, 11:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Tocilizumab vs Abatacept

NCT04529863
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tocilizumab, Abatacept
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
30,432 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Oct 21, 2026, 11:15 PM EDT
Not listed Not applicable Interventional

Improving Diabetes Equity and Advancing Care Study

NCT06040463
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Diabetes Self-Management Training (DSMT), Remote Glucose Monitoring (RGM), Community Health Worker tailored support
Behavioral
Lead sponsor
Sinai Health System
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Oct 21, 2026, 11:15 PM EDT